An OA phenotype may obtain major benefit from bone-acting agents

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 4, 2014, Pages 421-428

  Roman Blas, Jorge A ^a   Castañeda, Santos ^b   Largo, Raquel ^a   Lems, Willem F ^c   Herrero Beaumont, Gabriel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Articular cartilage; Bone agents; Osteoarthritis; Osteoporosis; Subchondral bone

Indexed keywords

ARTICULAR CARTILAGE; BONE AGENTS; OSTEOARTHRITIS; OSTEOPOROSIS; SUBCHONDRAL BONE;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CARTILAGE, ARTICULAR; HUMANS; OSTEOARTHRITIS;

EID: 84894900735     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.07.012     Document Type: Article

References (90)

1. Lane N.E., Brandt K., Hawker G., Peeva E., Schreyer E., Tsuji W., et al. OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis Cartilage 2011, 19:478-482.
2. Goldring M.B., Goldring S.R. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci 2010, 1192:230-237.
3. Herrero-Beaumont G., Roman-Blas J.A., Castañeda S., Jimenez S.A. Primary osteoarthritis no longer primary: three subsets with distinct etiological, clinical, and therapeutic characteristics. Semin Arthritis Rheum 2009, 39:71-80.
4. Pastoureau P.C., Chomel A.C., Bonnet J. Evidence of early subchondral bone changes in the meniscectomized guinea pig. A densitometric study using dual-energy X-ray absorptiometry subregional analysis. Osteoarthritis Cartilage 1999, 7:466-473.
5. Hayami T., Pickarski M., Zhuo Y., Wesolowski G.A., Rodan G.A., Duong le T., et al. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 2006, 38:234-243.
6. Day J.S., Ding M., van der Linden J.C., Hvid I., Sumner D.R., Weinans H., et al. A decreased subchondral trabecular bone tissue elastic modulus is associated with pre-arthritic cartilage damage. J Orthop Res 2001, 19:914-918.
7. Herrero-Beaumont G., Roman-Blas J.A., Largo R., Berenbaum F., Castañeda S. Bone mineral density and joint cartilage: four clinical settings of a complex relationship in osteoarthritis. Ann Rheum Dis 2011, 70:1523-1525.
8. Burr D.B., Gallant M.A. Bone remodelling in osteoarthritis. Nat Rev Rheumatol 2012, 8:665-673.
9. Brandt K.D., Myers S.L., Burr D., Albrecht M. Osteoarthritic changes in canine articular cartilage, subchondral bone, and synovium fifty-four months after transection of the anterior cruciate ligament. Arthritis Rheum 1991, 34:1560-1570.
10. Radin E.L., Burr D.B., Fyhrie D., Brown T.D., Boyd R.D. Characteristics of joint loading as it applies to osteoarthrosis. Biomechanics of Diarthrodial Joints 1990, 1:437-451. Springer-Verlag, New York.
11. Huebner J.L., Hanes M.A., Beekman B., TeKoppele J.M., Kraus V.B. A comparative analysis of bone and cartilage metabolism in two strains of guinea-pig with varying degrees of naturally occurring osteoarthritis. Osteoarthritis Cartilage 2002, 10:758-767.
12. Goldring S.R., Goldring M.B. Bone and cartilage in osteoarthritis: is what's best for one good or bad for the other?. Arthritis Res Ther 2010, 12:143.
13. Bellido M., Lugo L., Roman-Blas J.A., Castañeda S., Caeiro J.R., Dapia S., et al. Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. Arthritis Res Ther 2010, 12:R152.
14. Bellido M., Lugo L., Roman-Blas J.A., Castañeda S., Calvo E., Largo R., et al. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. Osteoarthritis Cartilage 2011, 19:1228-1236.
15. Lugo L., Villalvilla A., Gómez R., Bellido M., Sánchez-Pernaute O., Largo R., et al. Effects of PTH (1-34) on synoviopathy in an experimental model of osteoarthritis preceded by osteoporosis. Osteoarthritis Cartilage 2012, 20:1619-1630.
16. Castañeda S., Roman-Blas J.A., Largo R., Herrero-Beaumont G. Subchondral bone as a key target for osteoarthritis treatment. Biochem Pharmacol 2012, 83:315-323.
17. Hayami T., Pickarski M., Wesolowski G.A., McLane J., Bone A., Destefano J., et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004, 50:1193-1206.
18. Jones M.D., Tran C.W., Li G., Maksymowych W.P., Zernicke R.F., Doschak M.R. In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat. Arthritis Rheum 2010, 62:2726-2735.
19. Kadri A., Funck-Brentano T., Lin H., Ea H.K., Hannouche D., Marty C., et al. Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling. Ann Rheum Dis 2010, 69:1533-1538.
20. Funck-Brentano T., Lin H., Hay E., Ah Kioon M.D., Schiltz C., Hannouche D., et al. Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism. PLoS One 2012, 7:e33543.
21. Zhu S., Chen K., Lan Y., Zhang N., Jiang R., Hu J. Alendronate protects against articular cartilage erosion by inhibiting subchondral bone loss in ovariectomized rats. Bone 2013, 53:340-349.
22. Zhang L., Hu H., Tian F., Song H., Zhang Y. Enhancement of subchondral bone quality by alendronate administration for the reduction of cartilage degeneration in the early phase of experimental osteoarthritis. Clin Exp Med 2011, 11:235-243.
23. Shirai T., Kobayashi M., Nishitani K., Satake T., Kuroki H., Nakagawa Y., et al. Chondroprotective effect of alendronate in a rabbit model of osteoarthritis. J Orthop Res 2011, 29:1572-1577.
24. Strassle B.W., Mark L., Leventhal L., Piesla M.J., Jian L.i.X., Kennedy J.D., et al. Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease. Osteoarthritis Cartilage 2010, 18:1319-1328.
25. Yu D.G., Yu B., Mao Y.Q., Zhao X., Wang X.Q., Ding H.F., et al. Efficacy of zoledronic acid in treatment of osteoarthritis is dependent on the disease progression stage in rat medial meniscal tear model. Acta Pharmacol Sin 2012, 33:924-934.
26. Pelletier J.P., Troncy E., Bertaim T., Thibaud D., Goulet A.C., Abram F., et al. Treatment with tiludronic acid helps reduce the development of experimental osteoarthritis lesions in dogs with anterior cruciate ligament transection followed by reconstructive surgery: a 1-year study with quantitative magnetic resonance imaging. J Rheumatol 2011, 38:118-128.
27. Moreau M., Rialland P., Pelletier J.P., Martel-Pelletier J., Lajeunesse D., Boileau C., et al. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther 2011, 13:R98.
28. Manicourt D.H., Altman R.D., Williams J.M., Devogelaer J.P., Druetz-Van Egeren A., Lenz M.E., et al. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum 1999, 42:1159-1167.
29. Behets C., Williams J.M., Chappard D., Devogelaer 1 J.P., Manicourt D.H. Effects of calcitonin on subchondral trabecular bone changes and on osteoarthritic cartilage lesions after acute anterior cruciate ligament deficiency. J Bone Miner Res 2004, 19:1821-1826.
30. Sondergaard B.C., Ostergaard S., Christiansen C., Tankó L.B., Karsdal M.A. The effect of oral calcitonin on cartilage turnover and surface erosion in the ovariectomized rat model. Arthritis Rheum 2007, 56:2674-2678.
31. Nielsen R.H., Bay-Jensen A.C., Byrjalsen I., Karsdal M.A. Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover. Osteoarthritis Cartilage 2011, 19:466-473.
32. Sondergaard B.C., Catala-Lehnen P., Huebner A.K., Bay-Jensen A.C., Schinke T., Henriksen K., et al. Mice over-expressing salmon calcitonin have strongly attenuated osteoarthritic histopathological changes after destabilization of the medial meniscus. Osteoarthritis Cartilage 2012, 20:136-143.
33. Cheng T., Zhang L., Fu X., Wang W., Xu H., Song H., et al. The potential protective effects of calcitonin involved in coordinating chondrocyte response, extracellular matrix, and subchondral trabecular bone in experimental osteoarthritis. Connect Tissue Res 2013, 54:139-146.
34. El Hajjaji H., Williams J.M., Devogelaer J.P., Lenz M.E., Thonar E.J., Manicourt D.H. Treatment with calcitonin prevents the net loss of collagen, hyaluronan and proteoglycan aggregates from cartilage in the early stages of canine experimental osteoarthritis. Osteoarthritis Cartilage 2004, 12:904-911.
35. Kyrkos MJ, Papavasiliou KA, Kenanidis E, Tsiridis E, Sayegh FE, Kapetanos GA. Calcitonin delays the progress of early-stage mechanically induced osteoarthritis. In vivo, prospective study. Osteoarthritis Cartilage. 2013. 10.1016/j.joca.2013.03.011. [Epub ahead of print]. http://www.pii:S1063-4584(13)00736-X.
36. Ham K.D., Loeser R.F., Lindgren B.R., Carlson C.S. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum 2002, 46:1956-1964.
37. Ham K.D., Carlson C.S. Effects of estrogen replacement therapy on bone turnover in subchondral bone and epiphyseal metaphyseal cancellous bone of ovariectomized cynomolgus monkeys. J Bone Miner Res 2004, 19:823-829.
38. Christgau S., Tankó L.B., Cloos P.A., Mouritzen U., Christiansen C., Delaissé J.M., et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 2004, 11:508-518.
39. Oestergaard S., Sondergaard B.C., Hoegh-Andersen P., Henriksen K., Qvist P., Christiansen C., et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 2006, 54:2441-2451.
40. Yang J.H., Kim J.H., Lim D.S., Oh K.J. Effect of combined sex hormone replacement on bone/cartilage turnover in a murine model of osteoarthritis. Clin Orthop Surg 2012, 4:234-241.
41. Pelletier J.P., Kapoor M., Fahmi H., Lajeunesse D., Blesius A., Maillet J., et al. Strontium ranelate reduces the progression of experimental dog osteoarthritis by inhibiting the expression of key proteases in cartilage and of IL-1beta in the synovium. Ann Rheum Dis 2013, 72:250-257.
42. Yu D.G., Ding H.F., Mao Y.Q., Liu M., Yu B., Zhao X., et al. Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis model. Acta Pharmacol Sin 2013, 34:393-402.
43. McDougall J.J., Schuelert N., Bowyer J. Cathepsin K inhibition reduces CTXII levels and joint pain in the guinea pig model of spontaneous osteoarthritis. Osteoarthritis Cartilage 2010, 18:1355-1357.
44. Connor J.R., LePage C., Swift B.A., Yamashita D., Bendele A.M., Maul D., et al. Protective effects of a cathepsin K inhibitor, SB-553484, in the canine partial medial meniscectomy model of osteoarthritis. Osteoarthritis Cartilage 2009, 17:1236-1243.
45. Hayami T., Zhuo Y., Wesolowski G.A., Pickarski M., Duong l T. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone 2012, 50:1250-1259.
46. Nevitt M.C., Cummings S.R., Lane N.E., Hochberg M.C., Scott J.C., Pressman A.R., et al. Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1996, 156:2073-2080.
47. Spector T.D., Nandra D., Hart D.J., Doyle D.V. Is hormone replacement therapy protective for hand and knee osteoarthritis in women? The Chingford Study. Ann Rheum Dis 1997, 56:432-444.
48. Hart D.J., Doyle D.V., Spector T.D. Incidence and risk factors for radiographic knee osteoarthritis in middle-aged women: the Chingford Study. Arthritis Rheum 1999, 42:17-24.
49. Hannan M.T., Felson D.T., Anderson J.J., Naimark A., Kannel W.B. Estrogen use and radiographic osteoarthritis of the knee in women: the Framingham Osteoarthritis Study. Arthritis Rheum 1990, 33:525-532.
50. Zhang Y., McAlindon T.E., Hannan M.T., Chaisson C.E., Klein R., Wilson P.W., et al. Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham Study. Arthritis Rheum 1998, 41:1867-1873.
51. Carbone L.D., Nevitt M.C., Wildy K., Barrow K.D., Harris F., Felson D., et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004, 50:3516-3525.
52. Bagger Y.Z., Tanko L.B., Alexandersen P., Karsdal M.A., Olson M., Mindeholm L., et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 2005, 37:425-430.
53. Manicourt D.H., Azria M., Mindeholm L., Thonar E.J., Devogelaer J.P. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 2006, 54:3205-3211.
54. Karsdal M.A., Byrjalsen I., Henriksen K., Riis B.J., Lau E.M., Arnold M., et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthritis Cartilage 2010, 18:150-159.
55. Alexandersen P., Karsdal M.A., Byrjalsen I., Christiansen C. Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis. Climacteric 2011, 14:236-243.
56. Reginster Y.L., Badurski J., Bellamy N., Bensen W., Chapurlat R., Chevalier X., et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis 2013, 72:179-862012.
57. Spector T.D., Conaghan P.G., Buckland-Wright J.C., Garnero P., Cline G.A., Beary J.F., et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005, 7:R625-R633.
58. Bingham C.O., Buckland-Wright J.C., Garnero P., Cohen S.B., Dougados M., Adami S., et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006, 54:3494-3507.
59. Buckland-Wright J.C., Messent E.A., Bingham C.O., Ward R.J., Tonkin C. A 2yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 2007, 46:257-264.
60. Garnero P., Aronstein W.S., Cohen S.B., Conaghan P.G., Cline G.A., Christiansen C., et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 2008, 16:660-666.
61. Raynauld J.P., Martel-Pelletier J., Berthiaume M.J., Abram F., Choquette D., Haraoui B., et al. Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period. Ann Rheum Dis 2008, 67:683-688.
62. Laslett LL, Kingsbury SR, Hensor EMA, Bowes MA, Conaghan PG. Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative. **Ann Rheum Dis. published on line First [April 12, 2013]. http://dx.doi.org/10.1136/annrheumdis-2012-202989.
63. Laslett L.L., Doré D.A., Quinn S.J., Boon P., Ryan E., Winzenberg T.M., et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis 2012, 71:1322-1328.
64. Cirillo D.J., Wallace R.B., Wu L., Yood R.A. Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. Arthritis Rheum 2006, 54:3194-3204.
65. Neogi T., Nevitt M.C., Ensrud K.E., Bauer D., Felson D.T. The effect of alendronate on progression of spinal osteophytes and disc-space narrowing. Ann Rheum Dis 2008, 67:1427-1430.
66. Bruyere O., Delferriere D., Roux C., Wark J.D., Spector T., Devogelaer J.P., et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008, 67:335-339.
67. Bijlsma J.W., Berenbaum F., Lafeber F.P. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011, 377:2115-2126.
68. Chang J.K., Chang L.H., Hung S.H., Wu S.C., Lee H.Y., Lin Y.S., et al. Parathyroid hormone 1-34 inhibits terminal differentiation of human articular chondrocytes and osteoarthritis progression in rats. Arthritis Rheum 2009, 60:3049-3060.
69. Sampson E.R., Hilton M.J., Tian Y., Chen D., Schwarz E.M., Mooney R.A., et al. Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis. Sci Transl Med 2011, 3:101ra93.
70. Roman-Blas J.A., Castañeda S., Largo R., Herrero-Beaumont G. Osteoarthritis associated with estrogen deficiency. Arthritis Res Ther 2009, 11:241.
71. Calvo E., Castañeda S., Largo R., Fernández-Valle M.E., Rodríguez-Salvanés F., Herrero-Beaumont G. Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. Osteoarthritis Cartilage 2007, 15:69-77.
72. Castañeda S., Largo R., Calvo E., Bellido M., Gómez-Vaquero C., Herrero-Beaumont G. Effects of estrogen deficiency and low bone mineral density on healthy knee cartilage in rabbits. J Orthop Res 2010, 28:812-818.
73. Pastoureau P., Leduc S., Chomel A., De Ceuninck F. Quantitative assessment of articular cartilage and subchondral bone histology in the meniscectomized guinea pig model of osteoarthritis. Osteoarthritis Cartilage 2003, 11:412-423.
74. Rousseau J.C., Garnero P. Biological markers in osteoarthritis. Bone 2012, 51:265-277.
75. Woloszynski T., Podsiadlo P., Stachowiak G.W., Kurzynski M., Lohmander L.S., Englund M. Prediction of progression of radiographic knee osteoarthritis using tibial trabecular bone texture. Arthritis Rheum 2012, 64:688-695.
76. Keen H.I., Mease P.J., Bingham C.O., Giles J.T., Kaeley G., Conaghan P.G. Systematic review of MRI, ultrasound, and scintigraphy as outcome measures for structural pathology in interventional therapeutic studies of knee arthritis: focus on responsiveness. J Rheumatol 2011, 38:142-154.
77. Omoumi P., Mercier G.A., Lecouvet F., Simoni P., Van Berg B.C. CT arthrography, MR arthrography, PET, and scintigraphy in osteoarthritis. Radiol Clin North Am 2009, 47:595-615.
78. Hunter D.J. Insights from imaging on the epidemiology and pathophysiology of osteoarthritis. Radiol Clin North Am 2009, 47:539-551.
79. Hayashi D, Roemer FW, Guermazi A. Osteoarthritis year 2011 in review: imaging in OA-a radiologists' perspective. Osteoarthritis Cartilage 2012;20:207-214.
80. Conaghan P.G., Hunter D.J., Maillefert J.F., Reichmann W.M., Losina E. Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group. Osteoarthritis Cartilage 2011, 19:606-610.
81. Bruyere O., Dardenne C., Lejeune E., Zegels B., Pahaut A., Richy F., et al. Subchondral tibial bone mineral density predicts future joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis. Bone 2003, 32:541-545.
82. Clarke S., Wakeley C., Duddy J., Sharif M., Watt I., Ellingham K., et al. Dual-energy X-ray absorptiometry applied to the assessment of tibial subchondral bone mineral density in osteoarthritis of the knee. Skeletal Radiol 2004, 33:588-595.
83. Doré D., Quinn S., Ding C., Winzenberg T., Cicuttini F., Jones G. Subchondral bone and cartilage damage: a prospective study in older adults. Arthritis Rheum 2010, 62:1967-1973.
84. Lo G.H., Tassinari A.M., Driban J.B., Price L.L., Schneider E., Majumdar S., et al. Cross-sectional DXA and MR measures of tibial periarticular bone associate with radiographic knee osteoarthritis severity. Osteoarthritis Cartilage 2012, 20:686-693.
85. Akamatsu Y., Mitsugi N., Taki N., Kobayashi H., Saito T. Medial versus lateral condyle bone mineral density ratios in a cross-sectional study: a potential marker for medial knee osteoarthritis severity. Arthritis Care Res (Hoboken) 2012, 64:1036-1045.
86. Dieppe P., Cushnaghan J., Young P., Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis 1993, 52:557-563.
87. Addison S., Coleman R.E., Feng S., McDaniel G., Kraus V.B. Whole-body bone scintigraphy provides a measure of the total-body burden of osteoarthritis for the purpose of systemic biomarker validation. Arthritis Rheum 2009, 60:3366-3373.
88. Mazzuca S.A., Brandt K.D., Lane K.A., Chakr R. Malalignment and subchondral bone turnover in contralateral knees of overweight/obese women with unilateral osteoarthritis: implications for bilateral disease. Arthritis Care Res (Hoboken) 2011, 63:1528-1534.
89. Kraus V.B., McDaniel G., Worrell T.W., Feng S., Vail T.P., Varju G., et al. Association of bone scintigraphic abnormalities with knee malalignment and pain. Ann Rheum Dis 2009, 68:1673-1679.
90. Karsdal M.A., Alexandersen P., John M.R., Loeffler J., Arnold M., Azria M., et al. Oral calcitonin demonstrated symptom-modifying efficacy and increased cartilage volume: results from a 2-year phase 3 trial in patients with osteoarthritis of the knee. Osteoarthritis Cartilage 2011, 19(Suppl.1):S35.